Stockscreener 앱 받기
732.58
0.08%
0.62
전일 마감가:
$731.96
열려 있는:
$732.315
하루 거래량:
2.55M
Relative Volume:
0.59
시가총액:
$693.36B
수익:
$53.26B
순이익/손실:
$13.80B
주가수익비율:
47.88
EPS:
15.3
순현금흐름:
$-50.20M
1주 성능:
+2.94%
1개월 성능:
-3.98%
6개월 성능:
-19.07%
1년 성능:
-22.08%
1일 변동 폭
$728.50
$737.42
1주일 범위
$694.23
$746.59
52주 변동 폭
$623.78
$969.65
일라이 릴리 Stock (LLY) Company Profile
명칭
Lilly Eli Co
전화
(317) 276-2000
주소
LILLY CORPORATE CTR, INDIANAPOLIS, IN
LLY을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
732.58 | 656.17B | 53.26B | 13.80B | -50.20M | 15.30 |
|
JNJ
Johnson Johnson
|
177.17 | 422.54B | 90.62B | 22.66B | 18.18B | 9.35 |
|
ABBV
Abbvie Inc
|
210.40 | 367.30B | 58.33B | 3.73B | 18.24B | 2.10 |
|
NVS
Novartis Ag Adr
|
126.55 | 244.83B | 53.40B | 13.68B | 16.89B | 6.9231 |
|
MRK
Merck Co Inc
|
84.12 | 207.84B | 63.43B | 16.42B | 14.72B | 6.49 |
일라이 릴리 Stock (LLY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-27 | 업그레이드 | HSBC Securities | Reduce → Hold |
| 2025-08-18 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2025-08-07 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2025-06-05 | 다운그레이드 | Erste Group | Buy → Hold |
| 2025-04-28 | 다운그레이드 | HSBC Securities | Buy → Reduce |
| 2025-04-22 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-12-10 | 재개 | BofA Securities | Buy |
| 2024-11-15 | 개시 | Wolfe Research | Outperform |
| 2024-10-17 | 개시 | Bernstein | Outperform |
| 2024-09-13 | 재개 | Citigroup | Buy |
| 2024-08-12 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2024-02-21 | 다운그레이드 | DZ Bank | Buy → Hold |
| 2024-02-16 | 재확인 | Morgan Stanley | Overweight |
| 2023-12-21 | 다운그레이드 | Daiwa Securities | Buy → Outperform |
| 2023-11-09 | 개시 | Deutsche Bank | Hold |
| 2023-10-20 | 재개 | UBS | Buy |
| 2023-08-09 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-07-26 | 재확인 | Citigroup | Buy |
| 2023-07-14 | 개시 | HSBC Securities | Buy |
| 2023-05-24 | 재확인 | BofA Securities | Buy |
| 2023-05-24 | 재확인 | UBS | Buy |
| 2023-03-13 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-03-06 | 개시 | Jefferies | Hold |
| 2023-02-15 | 다운그레이드 | Societe Generale | Hold → Sell |
| 2022-11-18 | 개시 | Credit Suisse | Outperform |
| 2022-09-22 | 업그레이드 | UBS | Neutral → Buy |
| 2022-05-23 | 개시 | SVB Leerink | Outperform |
| 2022-04-06 | 재개 | Morgan Stanley | Overweight |
| 2022-03-10 | 개시 | Daiwa Securities | Outperform |
| 2022-01-21 | 업그레이드 | DZ Bank | Hold → Buy |
| 2022-01-03 | 재확인 | Bernstein | Mkt Perform |
| 2021-12-17 | 개시 | Goldman | Neutral |
| 2021-12-16 | 재확인 | BMO Capital Markets | Outperform |
| 2021-12-16 | 재확인 | BofA Securities | Buy |
| 2021-12-09 | 재개 | Wells Fargo | Equal Weight |
| 2021-11-19 | 개시 | BMO Capital Markets | Outperform |
| 2021-10-11 | 업그레이드 | Berenberg | Hold → Buy |
| 2021-09-29 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-08-05 | 업그레이드 | DZ Bank | Hold → Buy |
| 2021-07-27 | 재개 | Truist | Buy |
| 2021-06-24 | 재확인 | Cantor Fitzgerald | Overweight |
| 2021-01-19 | 업그레이드 | Mizuho | Neutral → Buy |
| 2020-12-10 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2020-11-10 | 재개 | Bernstein | Mkt Perform |
| 2020-09-29 | 개시 | Berenberg | Hold |
| 2020-09-03 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-06-16 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-04-21 | 다운그레이드 | UBS | Buy → Neutral |
| 2020-04-09 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-06 | 개시 | Mizuho | Neutral |
| 2019-12-18 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2019-10-17 | 재개 | BofA/Merrill | Buy |
| 2019-05-28 | 개시 | Goldman | Buy |
| 2019-04-24 | 업그레이드 | Edward Jones | Hold → Buy |
| 2019-04-11 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2019-03-12 | 개시 | JP Morgan | Overweight |
| 2019-01-23 | 개시 | UBS | Buy |
| 2018-11-26 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2018-10-31 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2018-10-09 | 개시 | Guggenheim | Buy |
| 2018-10-01 | 재확인 | SunTrust | Buy |
| 2018-09-26 | 재개 | JP Morgan | Overweight |
모두보기
일라이 릴리 주식(LLY)의 최신 뉴스
ESC25: Novo's Wegovy slashes CV risk by 57% over Lilly's Zepbound in real-world study - FirstWord Pharma
Can trapped investors hope for a rebound in Eli Lilly and Company2025 Key Lessons & Free Accurate Trade Setup Notifications - Newser
Can you recover from losses in Eli Lilly and CompanyJuly 2025 Levels & Verified Chart Pattern Trade Signals - Newser
HSBC Upgrades Eli Lilly (LLY) to Hold, Lifts Price Target to $700 - Yahoo Finance
Intraday pattern recognizer results for Eli Lilly and CompanyPortfolio Risk Report & Fast Exit Strategy with Risk Control - Newser
Benzinga Bulls And Bears: Eli Lilly, Firefly, Marvell — And Trump Investment Hints Boost Defense Stocks - inkl
Eli Lilly is close to launching the strongest weight-loss drug ever. Somehow, gym bros are already taking it to shred fat. - Business Insider
Eli Lilly and Company (LLY): A Bull Case Theory - MSN
Sector ETF performance correlation with Eli Lilly and Company2025 Geopolitical Influence & Consistent Profit Trading Strategies - Newser
Pharmaceutical Cos. Back Lilly In Mich. Insulin Pricing Probe - Law360
Jim Cramer Sees Big Potential in Eli Lilly’s Weight-Loss and Diabetes Pill - Yahoo Finance
The Zacks Analyst Blog Highlights Lilly, Oracle, Procter & Gamble and Comstock Holding Companies - ca.finance.yahoo.com
Eli Lilly (NYSE:LLY) vs Novo Nordisk (NYSE:NVO): Growth Premium vs Value Upside - tradingnews.com
Eli Lilly (NYSE:LLY) Stock Price Trading at $732 as GLP-1 Sales Surge and Drug Pricing Risks Rise - tradingnews.com
Lilly Is Angling For Approval Of Its Obesity Pill. Is It Now A Buy? - Investor's Business Daily
FDA Tightens Safety Guidelines For Biogen Leqembi Alzheimer's Therapy - Benzinga
Eli Lilly Temporarily Stops U.K. Shipments of Its Weight-Loss Drug - TipRanks
Eli Lilly Partners with JD Health for Direct-to-Consumer Obesity and Diabetes Drug Sales - AInvest
JD Health (06618.HK) has reached a strategic cooperation agreement with Eli Lilly and Co in China. - 富途牛牛
LLY Stock Quote Price and Forecast - CNN
Eli Lilly Partners With China Tech Giant for Obesity Drug Sales - Bloomberg.com
Eli Lilly to offer UK discount on Mounjaro weight-loss jabs - The Independent
Decoding Insider Activity at Eli Lilly: A Closer Look at Recent Share Sales and Buying Conviction - AInvest
Top Stock Reports for Eli Lilly, Oracle & Procter & Gamble - Nasdaq
Eli Lilly CIO Susan Ridlen retiring - Pensions & Investments
Eli Lilly (LLY) technical analysisEli Lilly (NYSE:LLY) - Benzinga
Eli Lilly (LLY) Reports Positive Outcomes for Verzenio in Breast Cancer Trial - uk.finance.yahoo.com
Lilly Obesity Deal Gives Superluminal More Shots On GPCR Goals - insights.citeline.com
Stockpiling frenzy prompts Lilly to suspend UK Mounjaro supply - FirstWord Pharma
U-turn on Mounjaro price hike: drug giant scales back planned rise after backlashnew costs revealed in full - Daily Mail
Eshelman Ventures, Eli Lilly back $11M round for RTP firm - The Business Journals
Truist Financial Sticks to Their Buy Rating for Eli Lilly & Co (LLY) - The Globe and Mail
UK Patients Scramble For Mounjaro As Eli Lilly's 170% Price Hike Plan Sparks Shortages, Health Fears - Benzinga
Eli Lilly temporarily halts UK shipments of weight-loss drug Mounjaro By Reuters - Investing.com
HSBC Upgrades Eli Lilly Amid 'More Sensible' Market Expectations for Weight Loss Pill - MarketScreener
Eli Lilly could bring first widely available GLP‑1 pill for obesity, diabetes to market this year - AOL.com
Stevens Capital Closes Out Position in Eli Lilly - The Motley Fool
Eli Lilly halts UK shipments of Mounjaro diabetes and weight-loss drug - Proactive Investors
Eli Lilly pauses shipments of weight loss drug Mounjaro to UK - The Guardian
Cautious Outlook on Eli Lilly’s Orforglipron Amid Promising Results and Competitive Challenges - TipRanks
Va. backs big pharma deals for AstraZeneca in Albemarle, Eli Lilly in Goochland - RealRadio804
Eli Lilly’s Orforglipron Successfully Completes Third Phase 3 Trial Resulting in Global Regulatory Submissions - PharmExec
Eli Lilly temporarily halts UK shipments of weight-loss drug Mounjaro - uk.finance.yahoo.com
Eli Lilly eyes orforglipron approval after Phase III diabetes trial success - Pharmaceutical Technology
This Eli Lilly Analyst Is No Longer Bearish; Here Are Top 4 Upgrades For Wednesday - Benzinga
Eli Lilly’s Stock (LLY) Is Upgraded by HSBC as Weight-Loss Pill Moves Closer to Approval - TipRanks
Eli Lilly stock rating reiterated at Outperform by BMO on orforglipron data - Investing.com
Eli Lilly stock maintains Buy rating at UBS after positive obesity drug data - Investing.com
Does Lilly's New Obesity Pill Data Put It Back in the Weight Game? - ca.finance.yahoo.com
Eli Lilly’s Promising Prospects: Buy Rating Backed by ATTAIN-2 Trial Success and Strategic Growth - TipRanks
The bear case on Eli Lilly has played out, says only firm to have called it a sell - MarketWatch
일라이 릴리 (LLY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.98%
자본화:
|
볼륨(24시간):